U.S. court favors Teva in migraine patent dispute with Lilly

March 31, 2020

The Patent Trial and Appeal Board (PTAB) upheld the validity of three Teva patents on its migraine treatment Ajovy, rejecting arguments by Eli Lilly that they were invalid.

Teva had previously accused Lilly’s competing drug Emgality of infringing the same patents. Lilly responded by asking PTAB to separately reconsider whether the patents should have been granted in the first place.

CGRP inhibitor Ajovy generated $96 million global sales for Teva last year.

Read the Reuters report